The words and actions of US President Donald Trump are rocking the pharmaceutical industry. On May 5, he said he…
BUSINESS
Gilead Shelves Sunlenca’s PrEP Program in Japan as Coverage Issue Weighs
Gilead Sciences is putting a hold on the Japan development of its anti-HIV therapy Sunlenca (lenacapavir) for pre-exposure prophylaxis (PrEP) due to the country’s reimbursement challenges for preventive medicines. This might give rise to a new drug loss if the…
To read the full story
Related Article
- Gilead Seeks Lawmakers’ Backing for Public Subsidies in PrEP
May 21, 2025
- MHLW Official Comments on PrEP Use of HIV Drugs: Diet
May 14, 2025
- Gilead Japan Revving Up Oncology Drive with Trodelvy, CAR-T as Legs of Growth
April 17, 2025
- KOL Calls for Public Support for Truvada’s PrEP Use against HIV
September 26, 2024
- Japan Approves Label Expansions for Alecensa, Nucala and More
August 29, 2024
- Gilead Files Truvada for HIV Prevention in Japan
February 29, 2024
- Gilead’s Multi-Drug Resistant HIV Med Now Available in Japan
September 14, 2023
BUSINESS
- Gilead Seeks Lawmakers’ Backing for Public Subsidies in PrEP
May 21, 2025
- Hiroaki Ueno to Retire as Representative Director of Mitsubishi Tanabe
May 21, 2025
- Sanofi Japan Seeing Improved Customer Satisfaction with AI-Powered Sales Support Tool
May 21, 2025
- 25 Japan Drug Makers’ Total Operating Profit Tops 2 Trillion Yen for 1st Time: Tally
May 20, 2025
- Chugai’s PNH Drug PiaSky Approved in Taiwan
May 20, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…